全文获取类型
收费全文 | 4981篇 |
免费 | 289篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 38篇 |
儿科学 | 123篇 |
妇产科学 | 153篇 |
基础医学 | 524篇 |
口腔科学 | 46篇 |
临床医学 | 863篇 |
内科学 | 866篇 |
皮肤病学 | 39篇 |
神经病学 | 468篇 |
特种医学 | 76篇 |
外科学 | 562篇 |
综合类 | 47篇 |
一般理论 | 4篇 |
预防医学 | 745篇 |
眼科学 | 96篇 |
药学 | 317篇 |
中国医学 | 1篇 |
肿瘤学 | 310篇 |
出版年
2024年 | 6篇 |
2023年 | 40篇 |
2022年 | 58篇 |
2021年 | 143篇 |
2020年 | 90篇 |
2019年 | 144篇 |
2018年 | 174篇 |
2017年 | 117篇 |
2016年 | 153篇 |
2015年 | 142篇 |
2014年 | 169篇 |
2013年 | 264篇 |
2012年 | 427篇 |
2011年 | 423篇 |
2010年 | 235篇 |
2009年 | 185篇 |
2008年 | 300篇 |
2007年 | 297篇 |
2006年 | 331篇 |
2005年 | 353篇 |
2004年 | 269篇 |
2003年 | 278篇 |
2002年 | 207篇 |
2001年 | 32篇 |
2000年 | 23篇 |
1999年 | 27篇 |
1998年 | 36篇 |
1997年 | 34篇 |
1996年 | 31篇 |
1995年 | 22篇 |
1994年 | 12篇 |
1993年 | 27篇 |
1992年 | 22篇 |
1991年 | 19篇 |
1990年 | 12篇 |
1989年 | 16篇 |
1988年 | 8篇 |
1987年 | 15篇 |
1986年 | 10篇 |
1985年 | 13篇 |
1984年 | 18篇 |
1983年 | 19篇 |
1982年 | 12篇 |
1981年 | 11篇 |
1980年 | 8篇 |
1979年 | 8篇 |
1978年 | 4篇 |
1976年 | 10篇 |
1975年 | 4篇 |
1969年 | 4篇 |
排序方式: 共有5278条查询结果,搜索用时 15 毫秒
71.
72.
73.
74.
Luca Micci Emily S. Ryan Rémi Fromentin Steven E. Bosinger Justin L. Harper Tianyu He Sara Paganini Kirk A. Easley Ann Chahroudi Clarisse Benne Sanjeev Gumber Colleen S. McGary Kenneth A. Rogers Claire Deleage Carissa Lucero Siddappa N. Byrareddy Cristian Apetrei Jacob D. Estes Jeffrey D. Lifson Michael Piatak Jr. Nicolas Chomont Francois Villinger Guido Silvestri Jason M. Brenchley Mirko Paiardini 《The Journal of clinical investigation》2015,125(12):4497-4513
Despite successful control of viremia, many HIV-infected individuals given antiretroviral therapy (ART) exhibit residual inflammation, which is associated with non–AIDS-related morbidity and mortality and may contribute to virus persistence during ART. Here, we investigated the effects of IL-21 administration on both inflammation and virus persistence in ART-treated, SIV-infected rhesus macaques (RMs). Compared with SIV-infected animals only given ART, SIV-infected RMs given both ART and IL-21 showed improved restoration of intestinal Th17 and Th22 cells and a more effective reduction of immune activation in blood and intestinal mucosa, with the latter maintained through 8 months after ART interruption. Additionally, IL-21, in combination with ART, was associated with reduced levels of SIV RNA in plasma and decreased CD4+ T cell levels harboring replication-competent virus during ART. At the latest experimental time points, which were up to 8 months after ART interruption, plasma viremia and cell-associated SIV DNA levels remained substantially lower than those before ART initiation in IL-21–treated animals but not in controls. Together, these data suggest that IL-21 supplementation of ART reduces residual inflammation and virus persistence in a relevant model of lentiviral disease and warrants further investigation as a potential intervention for HIV infection. 相似文献
75.
76.
77.
Michael J. Connor Jr Colleen Kraft Aneesh K. Mehta Jay B. Varkey G. Marshall Lyon Ian Crozier Ute Str?her Bruce S. Ribner Harold A. Franch 《Journal of the American Society of Nephrology : JASN》2015,26(1):31-37
AKI has been observed in cases of Ebola virus disease. We describe the protocol for the first known successful delivery of RRT with subsequent renal recovery in a patient with Ebola virus disease treated at Emory University Hospital, in Atlanta, Georgia. Providing RRT in Ebola virus disease is complex and requires meticulous attention to safety for the patient, healthcare workers, and the community. We specifically describe measures to decrease the risk of transmission of Ebola virus disease and report pilot data demonstrating no detectable Ebola virus genetic material in the spent RRT effluent waste. This article also proposes clinical practice guidelines for acute RRT in Ebola virus disease. 相似文献
78.
William R. Zhang Amit X. Garg Steven G. Coca Philip J. Devereaux John Eikelboom Peter Kavsak Eric McArthur Heather Thiessen-Philbrook Colleen Shortt Michael Shlipak Richard Whitlock Chirag R. Parikh 《Journal of the American Society of Nephrology : JASN》2015,26(12):3123-3132
Inflammation has an integral role in the pathophysiology of AKI. We investigated the associations of two biomarkers of inflammation, plasma IL-6 and IL-10, with AKI and mortality in adults undergoing cardiac surgery. Patients were enrolled at six academic centers (n=960). AKI was defined as a ≥50% or ≥0.3-mg/dl increase in serum creatinine from baseline. Pre- and postoperative IL-6 and IL-10 concentrations were categorized into tertiles and evaluated for associations with outcomes of in-hospital AKI or postdischarge all-cause mortality at a median of 3 years after surgery. Preoperative concentrations of IL-6 and IL-10 were not significantly associated with AKI or mortality. Elevated first postoperative IL-6 concentration was significantly associated with higher risk of AKI, and the risk increased in a dose-dependent manner (second tertile adjusted odds ratio [OR], 1.61 [95% confidence interval (95% CI), 1.10 to 2.36]; third tertile adjusted OR, 2.13 [95% CI, 1.45 to 3.13]). First postoperative IL-6 concentration was not associated with risk of mortality; however, the second tertile of peak IL-6 concentration was significantly associated with lower risk of mortality (adjusted hazard ratio, 0.75 [95% CI, 0.57 to 0.99]). Elevated first postoperative IL-10 concentration was significantly associated with higher risk of AKI (adjusted OR, 1.57 [95% CI, 1.04 to 2.38]) and lower risk of mortality (adjusted HR, 0.72 [95% CI, 0.56 to 0.93]). There was a significant interaction between the concentration of neutrophil gelatinase-associated lipocalin, an established AKI biomarker, and the association of IL-10 concentration with mortality (P=0.01). These findings suggest plasma IL-6 and IL-10 may serve as biomarkers for perioperative outcomes. 相似文献
79.
80.
Alice W. Tsai Colleen F. McNeil Joshua R. Leeman Hamilton B. Bennett Kwame Nti-Addae Cassey Huang Ursula A. Germann Randal A. Byrn Francoise Berlioz-Seux Rene Rijnbrand Michael P. Clark Paul S. Charifson Steven M. Jones 《Antimicrobial agents and chemotherapy》2015,59(10):6007-6016
Through antigenic drift and shifts, influenza virus infections continue to be an annual cause of morbidity in healthy populations and of death among elderly and at-risk patients. The emergence of highly pathogenic avian influenza viruses such as H5N1 and H7N9 and the rapid spread of the swine-origin H1N1 influenza virus in 2009 demonstrate the continued need for effective therapeutic agents for influenza. While several neuraminidase inhibitors have been developed for the treatment of influenza virus infections, these have shown a limited window for treatment initiation, and resistant variants have been noted in the population. In addition, an older class of antiviral drugs for influenza, the adamantanes, are no longer recommended for treatment due to widespread resistance. There remains a need for new influenza therapeutic agents with improved efficacy as well as an expanded window for the initiation of treatment. Azaindole compounds targeting the influenza A virus PB2 protein and demonstrating excellent in vitro and in vivo properties have been identified. To evaluate the in vivo efficacy of these PB2 inhibitors, we utilized a mouse influenza A virus infection model. In addition to traditional endpoints, i.e., death, morbidity, and body weight loss, we measured lung function using whole-body plethysmography, and we used these data to develop a composite efficacy score that takes compound exposure into account. This model allowed the rapid identification and ranking of molecules relative to each other and to oseltamivir. The ability to identify compounds with enhanced preclinical properties provides an opportunity to develop more-effective treatments for influenza in patients. 相似文献